

Irene Gañán-Gómez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1606977/publications.pdf>

Version: 2024-02-01

9
papers

198
citations

1478280

6
h-index

1372474

10
g-index

11
all docs

11
docs citations

11
times ranked

344
citing authors

#	ARTICLE	IF	CITATIONS
1	NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. <i>Blood Advances</i> , 2019, 3, 922-933.	2.5	84
2	KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice. <i>Blood Advances</i> , 2018, 2, 2491-2504.	2.5	29
3	Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. <i>Nature Medicine</i> , 2022, 28, 557-567.	15.2	26
4	Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes. <i>Leukemia</i> , 2020, 34, 872-881.	3.3	22
5	Hematopoiesis under telomere attrition at the single-cell resolution. <i>Nature Communications</i> , 2021, 12, 6850.	5.8	15
6	Down-regulation of EZH2 expression in myelodysplastic syndromes. <i>Leukemia Research</i> , 2016, 44, 1-7.	0.4	13
7	Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia. <i>Leukemia Research</i> , 2021, 101, 106511.	0.4	4
8	KDM6B Overexpression and TET2 Deficiency Cooperatively Drive Development of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia-like Phenotype in Mice. <i>Blood</i> , 2019, 134, 562-562.	0.6	2
9	Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia. <i>Leukemia</i> , 2022, 36, 2097-2107.	3.3	2